NHD Global
Metabolic & Weight Loss · Amylin analogue research
Scientific Product Dossier
Cagrilintide is a long-acting analogue of amylin, a hormone involved in fullness after eating. Research asks how this signaling pathway affects body weight and metabolic outcomes. Studies of cagrilintide alone and studies combining it with semaglutide answer different questions. This page covers the single ingredient; a blend has a separate catalog entry. Published trial results describe clinical preparations, while the selected NHD variant and its document status must be checked separately for research procurement.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
At 26 weeks, the trial reported mean body-weight changes from −6.0% to −10.8% across cagrilintide groups, compared with −3.0% for placebo.
Clinical monotherapy result for the studied intervention; not evidence for this catalog lot and not interchangeable with combination-trial outcomes.
Read the primary studyFDA states that cagrilintide is not a component of an FDA-approved drug and has not been found safe and effective for any condition.
Investigational status must remain visible wherever trial outcomes are summarized.
Read the primary studyGastrointestinal adverse events were reported in 41–63% of cagrilintide groups versus 32% with placebo; nausea was reported in 20–47% versus 18%.
Trial-level tolerability data for the studied intervention; not a catalog-lot safety claim.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Randomized, double-blind, placebo-controlled human research evaluating multiple cagrilintide groups over 26 weeks.
View primary recordPrimary trial-registry record for the cagrilintide monotherapy study.
View primary recordThird-party publications selected for direct relevance.
Lau DCW, et al. The Lancet. 2021;398:2160–2172. PMID 34798060 · DOI 10.1016/S0140-6736(21)01751-7
ClinicalTrials.gov record NCT03856047.
U.S. Food and Drug Administration. Content current through May 31, 2026.
Concise answers for researchers comparing identity, evidence and catalog variants.
A 26-week Phase 2 monotherapy trial in adults with overweight or obesity reported greater average weight reduction across cagrilintide groups than with placebo, and a larger reduction at the top dose than an active comparator. That is a clinical result for the studied subcutaneous product. It does not apply to research materials, other routes, or combination studies, which are different interventions.
The amylin pathway overlaps with gut signalling, so nausea, constipation, and diarrhoea are biologically plausible. These were among the most frequent events in the monotherapy trial. Studying tolerability alongside weight outcomes shows whether a dose can be sustained long enough for the mechanism to work. It also separates trial-level data from research materials, which were not administered or tested in that human research.
Cagrilintide is an investigational, long-acting acylated analogue of the peptide hormone amylin.
No. It remains an investigational compound in clinical development.
No. Combination trials study cagrilintide with semaglutide and cannot be attributed to cagrilintide monotherapy.
Tell us which records your project requires. Availability and scope must be confirmed for the selected material. Published papers are not batch certificates, and this page does not confirm that a lot-specific COA is available.
Request the storage conditions for the exact supplied form and selected variant. A temperature stated for another supplier or a clinical drug preparation is not a verified storage specification for NHD catalog material.
No. Cagrilintide is one ingredient. A blend contains both ingredients and needs its own composition and amount basis. A combination-trial outcome does not establish the effect of cagrilintide alone or verify a commercial blend.
Send the exact product name, selected catalog variant, required quantity, destination and documents needed for the project. Specify whether the amount refers to powder mass or measured peptide content. Availability, price, lead time and document scope require confirmation.
No. A paper describes the material and methods used in that study. It does not establish the identity, purity or content of a different supplied lot. Ask which records actually apply to the requested material; do not assume a COA is available.
Knowledge center
Owned educational content connected to this family.
A source-grounded guide to cagrilintide’s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.
Updated October 1, 2026
A clean comparison of cagrilintide, semaglutide and the studied CagriSema combination, including 2025–2026 phase 3 records and limits on transferring evidence.
Updated October 1, 2026
REDEFINE 1 tested cagrilintide and semaglutide together, each ingredient separately, and placebo. Comparing these four groups explains the result more clearly than adding numbers…
Updated October 9, 2026
The September 2026 REIMAGINE 5 announcement reported 12.4% versus 9.1% weight reduction. Understand the population, tested doses and limits of the comparison.
Updated October 10, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: CGL5 · 5 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
